Our Offices

Monadelphous Successfully Challenges R&D Tax Dispute Following Conclusion of Internal Review

One of the most high profile R&D Tax disputes has been that of engineering contractor Monadelphous. In August 2019 Monadelphous recognised a $7 Million provision relating to repayment of R&D Claims for the FY15 and FY16 periods. The provision indicated […]

Significant Refundable R&D Offsets Receipts Reported to ASX, ATO Reviews Still Occurring

Over recent months, a number of companies have reported to the ASX receipt of substantial Refundable R&D Offsets. Notable receipts include: Zelira Therapeutics’ receipt of $1.4 M in December for cannabis medicines; Imugene’s receipt of $4.82M in December for Immuno-oncology […]